2018 Thromboembolism Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Thromboembolism Market
Thrombosis refers to a blood vessel related condition in which a clot inside the arteries or veins affects the flow from and to the heart of the patient. Based on the area of formation of clot, thrombosis is classified as Venous Thromboembolism (VTE) and Arterial Thromboembolism.
In Europe alone, over 0.7 million people are given anticoagulant treatment for prevention or treating thrombosis.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Thromboembolism pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Thromboembolism pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Thromboembolism pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
In Europe alone, over 0.7 million people are given anticoagulant treatment for prevention or treating thrombosis.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Thromboembolism pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Thromboembolism pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Thromboembolism pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 THROMBOEMBOLISM PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Thromboembolism Pipeline Snapshot
2.3 Thromboembolism Pipeline by Phase
2.4 Thromboembolism Pipeline by Company
2.5 Thromboembolism Pipeline by Mechanism of Action
3 THROMBOEMBOLISM- COMPANY WISE PIPELINE ANALYSIS
Arrowhead Pharmaceuticals, Inc
Bayer AG
China Biologic Products Holdings, Inc.
Daiichi Sankyo Company, Limited
Ionis Pharmaceuticals Inc
Janssen Pharmaceuticals, Inc.
Lee's Pharmaceutical Holdings
Pfizer Inc
Prothix BV
Quercegen Pharmaceuticals LLC
Roche Holding AG
Shandong Taibang Biological Products Co.Ltd.
TeaRx Ltd.
Verseon Corp
4 THROMBOEMBOLISM R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN THROMBOEMBOLISM PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 THROMBOEMBOLISM PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Thromboembolism Pipeline Snapshot
2.3 Thromboembolism Pipeline by Phase
2.4 Thromboembolism Pipeline by Company
2.5 Thromboembolism Pipeline by Mechanism of Action
3 THROMBOEMBOLISM- COMPANY WISE PIPELINE ANALYSIS
Arrowhead Pharmaceuticals, Inc
Bayer AG
China Biologic Products Holdings, Inc.
Daiichi Sankyo Company, Limited
Ionis Pharmaceuticals Inc
Janssen Pharmaceuticals, Inc.
Lee's Pharmaceutical Holdings
Pfizer Inc
Prothix BV
Quercegen Pharmaceuticals LLC
Roche Holding AG
Shandong Taibang Biological Products Co.Ltd.
TeaRx Ltd.
Verseon Corp
4 THROMBOEMBOLISM R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN THROMBOEMBOLISM PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Thromboembolism Pipeline by Phase, H2- 2018
Figure 2: Thromboembolism Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Thromboembolism Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
Figure 1: Thromboembolism Pipeline by Phase, H2- 2018
Figure 2: Thromboembolism Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Thromboembolism Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
LIST OF TABLES
Thromboembolism Pipeline by Phase, H2- 2018
Thromboembolism Pipeline by Companies, H2- 2018
Thromboembolism Pipeline by Mechanism of Action, H2- 2018
Table 1: Arrowhead Pharmaceuticals, Inc Thromboembolism Pipeline Drugs, H2- 2018
Table 2: Bayer AG Thromboembolism Pipeline Drugs, H2- 2018
Table 3: China Biologic Products Holdings, Inc. Thromboembolism Pipeline Drugs, H2- 2018
Table 4: Daiichi Sankyo Company, Limited Thromboembolism Pipeline Drugs, H2- 2018
Table 5: Ionis Pharmaceuticals Inc Thromboembolism Pipeline Drugs, H2- 2018
Table 6: Janssen Pharmaceuticals, Inc. Thromboembolism Pipeline Drugs, H2- 2018
Table 7: Lee's Pharmaceutical Holdings Thromboembolism Pipeline Drugs, H2- 2018
Table 8: Pfizer Inc Thromboembolism Pipeline Drugs, H2- 2018
Table 9: Prothix BV Thromboembolism Pipeline Drugs, H2- 2018
Table 10: Quercegen Pharmaceuticals LLC Thromboembolism Pipeline Drugs, H2- 2018
Table 11: Roche Holding AG Thromboembolism Pipeline Drugs, H2- 2018
Table 12: Shandong Taibang Biological Products Co.Ltd. Thromboembolism Pipeline Drugs, H2- 2018
Table 13: TeaRx Ltd. Thromboembolism Pipeline Drugs, H2- 2018
Table 14: Verseon Corp Thromboembolism Pipeline Drugs, H2- 2018
Thromboembolism Pipeline by Phase, H2- 2018
Thromboembolism Pipeline by Companies, H2- 2018
Thromboembolism Pipeline by Mechanism of Action, H2- 2018
Table 1: Arrowhead Pharmaceuticals, Inc Thromboembolism Pipeline Drugs, H2- 2018
Table 2: Bayer AG Thromboembolism Pipeline Drugs, H2- 2018
Table 3: China Biologic Products Holdings, Inc. Thromboembolism Pipeline Drugs, H2- 2018
Table 4: Daiichi Sankyo Company, Limited Thromboembolism Pipeline Drugs, H2- 2018
Table 5: Ionis Pharmaceuticals Inc Thromboembolism Pipeline Drugs, H2- 2018
Table 6: Janssen Pharmaceuticals, Inc. Thromboembolism Pipeline Drugs, H2- 2018
Table 7: Lee's Pharmaceutical Holdings Thromboembolism Pipeline Drugs, H2- 2018
Table 8: Pfizer Inc Thromboembolism Pipeline Drugs, H2- 2018
Table 9: Prothix BV Thromboembolism Pipeline Drugs, H2- 2018
Table 10: Quercegen Pharmaceuticals LLC Thromboembolism Pipeline Drugs, H2- 2018
Table 11: Roche Holding AG Thromboembolism Pipeline Drugs, H2- 2018
Table 12: Shandong Taibang Biological Products Co.Ltd. Thromboembolism Pipeline Drugs, H2- 2018
Table 13: TeaRx Ltd. Thromboembolism Pipeline Drugs, H2- 2018
Table 14: Verseon Corp Thromboembolism Pipeline Drugs, H2- 2018
